Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics will go public soon. The estimated IPO date is February 5, 2026.
IPO Price Range
$16.00 - $18.00
Shares Offered
17,648,000
Deal Size
$300.02M
Company Description
Eikon Therapeutics is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs.
Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.
Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.
We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.
Eikon Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 5, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Roger M. Perlmutter, M.D., Ph.D. |
Contact Details
Address: 230 Harriet Tubman Way Millbrae, CA 94030 United States | |
| Phone | (341) 777-0566 |
| Website | eikontx.com |
Stock Details
| Ticker Symbol | EIKN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1861123 |
| Employer ID | 84-2807586 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Roger M. Perlmutter, M.D., Ph.D. | Chief Executive Officer, Chair and Director |
| Roy Baynes, M.D. Ph.D. | Chief Medical Officer |
| Alfred Bowie, Ph.D. | Chief Financial Officer |
| Michael Klobuchar | Chief Operating Officer |
| Benjamin Thorner | Chief Business Officer and General Counsel |
| Dror Berman | Director |
| Leon Chen, Ph.D. | Director |
| Kenneth C. Frazier | Director |
| Robert Huffines | Director |
| David Meline | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 4, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jan 30, 2026 | EFFECT | Notice of Effectiveness |
| Jan 28, 2026 | 8-A12B | Registration of securities |
| Jan 28, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 12, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 26, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 1, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 9, 2025 | DRS | [Cover] Draft Registration Statement |
| Feb 28, 2025 | D | Notice of Exempt Offering of Securities |